MRMelissa M. Ronan

Melissa M. Ronan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa M. Ronan has a total of 703 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PLK4 inhibition-mediated centrosome amplification drives anti-tumor activity across euploid solid tumors

    by Nina M. Muñoz, Christopher W. Szeto, Pragalath Sundararajan, Kaleo Leonhardt, Akhil Choppa, Christopher Kochansky, Jo-Ting Chang, Jimmy Lai, Rizlane Nghima-Tahiri, Jennifer A. Roth, et al.

  • Open Access

    Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300

    by Ian M. Delahunty, Stephanie Nance, Yang Zhang, Francois Lamoureux, Qi Liu, William C. Wright, K. Elaine Ritter, Noha A.M. Shendy, Bénédicte Brounais-Le Roye, Sandra J. Kietlinska, et al.

    Cancers depend on transcriptional control to maintain the malignant cell state. EP300 and CBP are paralogous master epigenetic enzymes that control normal and malignant transcription. Using a cancer-wide integrative chemical-genetic analysis, we demonstrate enhanced dependency on EP300, compared with CBP, in cell lines from most cancer lineages, including lethal osteosarcoma (OS). Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K–AKT–mTOR pathway is genetically and chemically sensitive to loss of EP300. Activated AKT promotes sensitivity to JQAD1, driven by relocalization of EP300, CBP and H3K27ac to genetic subtype-enriched dependency loci. AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro and in orthotopic xenografts. These observations extend across >850 cancer cell lines, where synergy is predicted by elevated protein synthetic rates. These findings reveal determinants of EP300 degrader function in OS and provide a foundation for co-targeting EP300 and AKT in cancers with enhanced protein translation.

  • Open Access

    A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo

    by Linda Julian, Lisa Crozier, Devon Lukow, Aditi Swamy, Sanat Mishra, Ryan A. Hagenson, Peter Sennhenn, Erin L. Sausville, Amy J. S. McGeoch, Sarah L. Thompson, et al.

    The cyclin-dependent kinase CDK11 is an understudied kinase that has been the subject of conflicting reports regarding its function in cancer. Here, we combine genetic and pharmacological approaches to demonstrate that CDK11 is a critical regulator of cancer cell survival that is required for RNA splicing and the expression of homologous recombination genes. Inhibition of CDK11 disrupts genome stability, promotes the retention of intronic sequences in mature mRNAs, and induces synthetic lethality with PARP inhibitors. Through integrative analysis of functional genomics datasets, we identify heterozygous deletions of chromosome 1p36 - which encompasses CDK11 and its activating cyclin CCNL2 - as a recurrent and predictive biomarker of sensitivity to CDK11 inhibition. To assess the therapeutic potential of CDK11, we establish a genetically-engineered mouse model that allows us to differentiate between the on-target and off-target effects of CDK11 inhibitors in vivo. Using this platform, we demonstrate that MEL-495R, an orally bioavailable CDK11 inhibitor, induces widespread on-target toxicity, revealing a narrow therapeutic index. Experiments with a chemically distinct CDK11 inhibitor similarly reveal minimal anti-cancer activity at tolerable doses. Together, these findings define CDK11 as a core cancer dependency, uncover a chromosomal deletion that sensitizes tumors to CDK11 inhibition, demonstrate that on-target toxicity limits the efficacy of CDK11-targeting therapies, and provide a generalizable strategy for deconvolving drug efficacy and toxicity in vivo for novel oncology targets.

  • Open Access

    Targeting O6-methylguanine-DNA Methyltransferase Deficiency in Preclinical Models of Extracranial Human Cancers with a Tumor-Selective DNA-Modifying Agent

    by Ranjini K. Sundaram, Spenser S. Johnson, Siddhant P. Bhoir, Vijay Menon, Kingson Lin, Collin D. Heer, Prateek Bhardwaj, Teresa Lee, Deepti Bhatt, Danielle M. Burgenske, et al.

    Temozolomide (TMZ) is an established therapy for gliomas with silencing of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) but is hindered by the frequent development of resistance via loss of mismatch repair (MMR) proteins. To overcome this resistance, a novel 2-fluoroethylating agent, KL-50, was designed to generate toxic DNA interstrand cross-links specifically in MGMT-deficient cells, bypassing MMR. KL-50 has shown efficacy in preclinical MGMT-silenced, TMZ-resistant glioma models. MGMT loss also occurs in a wide range of nonglioma cancers, but the ability of KL-50 to effectively treat these tumors with minimal off-target toxicity remains untested. In this study, we utilize a large-scale cell-line screen, focused panels of cancer cell lines, and tumor xenograft mouse models, including patient-derived xenografts, to interrogate the therapeutic potential of KL-50 in treating intracranial and extracranial tumors. We find that KL-50 is highly efficacious in a wide range of MGMT-deficient human tumor models, including colon cancer, melanoma, and lung cancer in vivo models. In addition, we demonstrate that KL-50 is impervious to loss of MMR and remains effective in tumors with induced TMZ resistance. Finally, we determine that KL-50 possesses higher MGMT selectivity in vitro compared with chloroethylating agents and is associated with less in vivo systemic toxicity in preclinical models. These results establish KL-50 as the first agent to maintain strong selectivity for MGMT loss while inducing tumor toxicity by an MMR-independent mechanism and support further development of 2-fluoroethylating agents for use in a tumor type–agnostic, biomarker-based strategy targeting MGMT-deficient tumors.

  • Open Access

    A design approach for bitopic kinase inhibitors

    by Jack W. Stevenson, Kevin Lou, Joshua A. Reynolds, Ian R. Outhwaite, Kenneth Huang, Ivan Sokirniy, Sky Y. J. Peterson, Amir Z. Munir, Celine D. Wang, Haider Inam, et al.

    Traditional kinase inhibitors face a trade-off between potency and selectivity because their affinity depends on limited molecular interactions in a single highly conserved binding site. Bitopic inhibitors overcome this limitation by engaging multiple sites on the same target 1 . Here, using ABL1 and EGFR as model kinases, we systematically explore the bitopic-specific design parameters of ligand choice, linkage vector and linker length and show that they affect potency through inter-ligand cooperativity and linker entropy. We apply this approach to address an unmet clinical need: existing inhibitors of ABL1, an important target in BCR :: ABL1 -driven leukaemias, are constrained by resistance mutations and off-target effects 2 . The third-generation inhibitor ponatinib overcomes many resistance mutations, but cardiovascular toxicity limits its clinical use 3 . We design a bitopic ABL1 inhibitor, PonatiLink-2, that maintains or surpasses the potency of ponatinib against resistance mutants. Moreover, it has an enhanced therapeutic window in vitro and in vivo, which enables increased dosing without apparent toxicity. PonatiLink-2 outperforms clinically relevant treatments in mouse models of BCR :: ABL1 -driven cancer, both in combination with dasatinib against wild-type BCR :: ABL1 and as a single agent against ponatinib-resistant disease. These findings indicate that the bitopic design approach is a promising strategy for developing potent, well-tolerated clinical inhibitors of ABL1 and other targets.


  • Open Access

    Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response

    by Zheqi Li, Amatullah Tawawalla, Pierre Foidart, Marco Seehawer, Jun Nishida, Ernesto Rojas Jimenez, Triet M. Bui, Xiao-Yun Huang, Matthew G. Rees, Melissa M. Ronan, et al.

    Triple-negative breast cancer (TNBC) has poor outcomes and few effective treatments, partly because of epigenetic heterogeneity. We show that the heterochromatin mark H4K20me3 is more variable than H3K9me3 across normal and malignant breast tissues, and that H4K20me3-enriched regions are linked to more open chromatin and active transcription. Pharmacologic inhibition of the H4K20me3 methyltransferases KMT5B and KMT5C with A-196 decreases H4K20me3 and increases H4K20me1 at loci involved in lineage identity, stress responses, and the cell cycle. A-196 suppresses tumor growth in vivo while promoting mesenchymal features and the unfolded protein response (UPR). Multi-omic profiling shows that mesenchymal TNBCs have the lowest H4K20me3 levels and the greatest sensitivity to UPR stress. In basal TNBC, KMT5B&5 C inhibition drives mesenchymal transition and elevated endoplasmic reticulum stress-associated growth arrest via E2F4. Combining A-196 with the HSP90, IRAK4 inhibitors, or STING agonist synergistically reduces TNBC tumor growth. These findings nominate KMT5B&5C as promising therapeutic targets in TNBC.

  • Open Access

    Supplementary Table S5 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma

    by Mona Foth, Wontak Kim, Kayla O’TOole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Boggaram, Phaedra Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, et al.

    DNA primers used for PCR or Sanger seq.

  • Open Access

    Supplementary Table S7 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma

    by Mona Foth, Wontak Kim, Kayla O’TOole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Boggaram, Phaedra Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, et al.

    Quantitative PCR (qPCR) primers used on gDNA.

  • Open Access

    Supplementary Table S4 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma

    by Mona Foth, Wontak Kim, Kayla O’TOole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Boggaram, Phaedra Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, et al.

    Patient-derived xenografts (PDXs).

  • Open Access

    Supplementary Table S6 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma

    by Mona Foth, Wontak Kim, Kayla O’TOole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Boggaram, Phaedra Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, et al.

    CRISPR guideRNAs and associated primers.